Anika Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2024 Earnings Call Transcript
Barrington Research: Maintaining the Anika Therapeutics (ANIK.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $37.00 to $37.00.
Barrington Research: Maintaining the Anika Therapeutics (ANIK.US) rating, adjusted from better than market to better than market rating, and adjusted the target price from $37.00 to $37.00.
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $37 Price Target
Barrington Research analyst Michael Petusky maintains Anika Therapeutics with a Outperform and maintains $37 price target.
Anika Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 41.76% Barrington Research $37 → $37 Maintains Outperform 03/14/2024 41.76% Barrington Research
Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Anika Therapeutics (ANIK)
Anika Therapeutics, Inc. (ANIK) Q1 2024 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q1 2024 Earnings Call Transcript
Anika Names Steve Griffin as New Finance Chief
By Mary de Wet Anika Therapeutics appointed Steve Griffin as chief financial officer, executive vice president and treasurer, effective June 3. Griffin, the former finance chief for VSE, succeeds Mi
Anika Says Cost Reduction Initiatives Complete; Says On-Track For FY24 Revenue Guidance Of $168M-$173M (Est $170.272M)
The Company expects adjusted EBITDA for 2024 to be $25 to $30 million, up over 75% at the midpoint, representing an adjusted EBITDA margin of at least 15%, up over 600 basis points compared to 2023.
Anika Announces Steve Griffin Appointed To CFO, Effective June 3, 2024
Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has appointed Steve Griffin as the Company's Executive Vice Presi
Anika Therapeutics | 10-Q: Quarterly report
Anika Therapeutics Appoints Steve Griffin as Finance Chief
Anika Therapeutics Announces New CFO and Executive Changes
Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q1 EPS $0.09
04:14 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q1 EPS $0.09
Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q1 Revenue $40.5M, Vs. Street Est of $39.1M
04:13 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q1 Revenue $40.5M, vs. Street Est of $39.1M
Anika Therapeutics Q1 2024 Adj EPS $0.09 Beats $(0.19) Estimate, Sales $40.523M Beat $39.143M Estimate
Anika Therapeutics (NASDAQ:ANIK) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.19) by 147.37 percent. The company reported quarterly sales of $40.523
Anika Therapeutics Appoints Steve Griffin as CFO Effective June 3 >ANIK
Anika Therapeutics Appoints Steve Griffin as CFO Effective June 3 >ANIK
Anika Therapeutics Former CFO Michael Levitz Will Remain With Co Through Dec 31 >ANIK
Anika Therapeutics Former CFO Michael Levitz Will Remain With Co Through Dec 31 >ANIK
Press Release: Anika Announces CFO Transition
Anika Announces CFO Transition Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024 BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a glo
Anika Announces CFO Transition
Steve Griffin Appointed Chief Financial Officer, Effective June 3, 2024BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company i
No Data